# LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

> **NCT02888236** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 32731
- **DRUG:** LEO 32731 Placebo

## Key facts

- **NCT ID:** NCT02888236
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-06-20
- **Final completion:** 2017-07-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02888236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02888236, "LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02888236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*